Serina Therapeutics (NYSEAMERICAN:SER) Issues Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) released its quarterly earnings results on Thursday. The company reported ($0.55) earnings per share for the quarter, FiscalAI reports.

Serina Therapeutics Stock Down 1.8%

Serina Therapeutics stock traded down $0.05 during trading hours on Friday, hitting $2.80. 75,950 shares of the stock traded hands, compared to its average volume of 44,893. Serina Therapeutics has a one year low of $1.22 and a one year high of $7.92. The firm’s 50-day moving average price is $2.09 and its two-hundred day moving average price is $2.02. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24. The company has a market cap of $42 million, a PE ratio of -1.48 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Separately, BTIG Research started coverage on shares of Serina Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $8.00.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.